Altrius Capital Management Inc Has $5.05 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Altrius Capital Management Inc boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 97,662 shares of the biopharmaceutical company’s stock after acquiring an additional 620 shares during the quarter. Altrius Capital Management Inc’s holdings in Bristol-Myers Squibb were worth $5,053,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BMY. M&G Plc acquired a new stake in Bristol-Myers Squibb in the 1st quarter valued at $392,608,000. Mizuho Markets Americas LLC purchased a new position in Bristol-Myers Squibb during the 1st quarter worth $11,931,000. First Foundation Advisors boosted its holdings in Bristol-Myers Squibb by 20.1% during the 1st quarter. First Foundation Advisors now owns 3,270 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 548 shares during the last quarter. Te Ahumairangi Investment Management Ltd boosted its holdings in Bristol-Myers Squibb by 2.9% during the 1st quarter. Te Ahumairangi Investment Management Ltd now owns 149,957 shares of the biopharmaceutical company’s stock worth $8,132,000 after acquiring an additional 4,250 shares during the last quarter. Finally, Nicolet Advisory Services LLC boosted its holdings in Bristol-Myers Squibb by 62.5% during the 1st quarter. Nicolet Advisory Services LLC now owns 12,600 shares of the biopharmaceutical company’s stock worth $650,000 after acquiring an additional 4,844 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BMY. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $55.00 to $73.00 in a report on Tuesday. UBS Group lifted their price objective on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Morgan Stanley boosted their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a report on Tuesday. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a report on Friday. They issued a “peer perform” rating on the stock. Finally, Jefferies Financial Group boosted their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $54.07.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded down $1.48 during midday trading on Friday, reaching $57.02. The stock had a trading volume of 4,146,137 shares, compared to its average volume of 14,386,111. The firm’s 50-day moving average price is $52.58 and its 200 day moving average price is $47.15. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The firm has a market capitalization of $115.65 billion, a PE ratio of -15.92, a P/E/G ratio of 15.83 and a beta of 0.44. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the prior year, the business posted $2.00 earnings per share. The company’s revenue was up 8.4% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.21%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -66.85%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.